Literature DB >> 7930297

The appropriate use of skin testing and allergen immunotherapy in young children.

D R Ownby1, A D Adinoff.   

Abstract

Immunotherapy is clearly effective in the treatment of allergic rhinitis and Hymenoptera sensitivity and probably effective in the treatment of asthma. Few studies evaluate the risks and benefits of immunotherapy in young children. Current evidence suggests that young children are at increased risk for systemic reactions from immunotherapy. Furthermore, immunotherapy or adverse reactions resulting from immunotherapy may result in significant psychologic problems. The potential risks of immunotherapy would be justified if immunotherapy were demonstrated to be safe and additive to other therapies. Immunotherapy might be particularly effective in treating or helping to prevent house dust mite- or cockroach-associated asthma. Until the efficacy of immunotherapy is demonstrated in young children, we agree with the European Academy of Allergology and Clinical Immunology position that immunotherapy in young children is relatively contraindicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930297     DOI: 10.1016/0091-6749(94)90171-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Pollen immunotherapy: selection,prevention, and future directions.

Authors:  Steven J McEldowney; Robert K Bush
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

2.  Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).

Authors:  Eric Leith; Tom Bowen; Joe Butchey; David Fischer; Harold Kim; Bill Moote; Peter Small; Don Stark; Susan Waserman
Journal:  Allergy Asthma Clin Immunol       Date:  2006-06-15       Impact factor: 3.406

3.  The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergists.

Authors:  Jason Behrmann
Journal:  Allergy Asthma Clin Immunol       Date:  2010-09-15       Impact factor: 3.406

4.  Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy.

Authors:  H Maazi; S Shirinbak; L E den Boef; F Fallarino; C Volpi; M C Nawijn; A J M van Oosterhout
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 5.  Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology.

Authors: 
Journal:  CMAJ       Date:  1995-05-01       Impact factor: 8.262

6.  Looking ahead at the potential benefits of biotechnology-derived allergen therapeutics.

Authors:  Jason Behrmann
Journal:  Clin Mol Allergy       Date:  2007-07-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.